#1 Clinical Trials Search in Europe

Pegaspargase

Pegaspargase is an important chemotherapy drug being studied in clinical trials for various lymphoid malignancies, including acute lymphoblastic leukemia (ALL), lymphomas, and other blood cancers. This article explores recent clinical trials investigating pegaspargase alone or in combination with other therapies to improve outcomes for patients with these challenging diseases.

Table of Contents

What is Pegaspargase?

Pegaspargase is a chemotherapy drug used in the treatment of various blood cancers. It’s a modified version of the enzyme L-asparaginase, which has been used for over 30 years in cancer treatment[1]. The “peg” in pegaspargase stands for “polyethylene glycol,” a substance added to the enzyme to make it last longer in the body and potentially reduce allergic reactions[2].

Pegaspargase is also known by several other names, including:

  • Oncaspar
  • PEG-asparaginase
  • SC-PEG asparaginase
  • Calaspargase Pegol

What Conditions Does Pegaspargase Treat?

Pegaspargase is primarily used to treat several types of blood cancers and lymphomas, including:

  • Acute Lymphoblastic Leukemia (ALL): This is a type of blood cancer that affects white blood cells called lymphocytes[1].
  • Lymphoblastic Lymphoma: A cancer that affects lymphocytes in the lymph nodes[1].
  • Extranodal NK/T-cell Lymphoma (ENKTL): A rare and aggressive type of non-Hodgkin lymphoma[3].
  • Non-Hodgkin’s Lymphoma: A group of blood cancers that develop from lymphocytes[2].
  • Hodgkin’s Lymphoma: Another type of lymphoma that affects the lymphatic system[2].
  • Multiple Myeloma: A cancer of plasma cells, which are a type of white blood cell[2].

How Does Pegaspargase Work?

Pegaspargase works by depleting a specific amino acid called asparagine in the blood. Cancer cells, particularly leukemia cells, rely heavily on asparagine for survival and growth. Unlike normal cells, many cancer cells can’t produce their own asparagine and must obtain it from the bloodstream. By reducing the amount of asparagine in the blood, pegaspargase essentially “starves” the cancer cells, leading to their death[1][2].

How is Pegaspargase Administered?

Pegaspargase is typically administered in the following ways:

  • Intravenous (IV) infusion: The drug is given directly into a vein over a period of time, usually about an hour[1].
  • Intramuscular (IM) injection: The drug is injected into a muscle, often in multiple sites due to the volume of the dose[3].

The dosage and frequency of administration can vary depending on the specific condition being treated, the patient’s body surface area, and other factors. For example, in some protocols, pegaspargase is given every 2-3 weeks for a total of 30 weeks[1].

Current Clinical Trials and Research

Several ongoing clinical trials are exploring new ways to use pegaspargase and improve its effectiveness:

  • Combining pegaspargase with other drugs to enhance its effectiveness. For example, a study is looking at combining pegaspargase with gemcitabine and oxaliplatin (P-Gemox) for treating extranodal NK/T-cell lymphoma[3].
  • Investigating the optimal dosing and scheduling of pegaspargase to maximize its benefits while minimizing side effects[1].
  • Exploring the use of pegaspargase in combination with newer targeted therapies, such as PD-1 inhibitors like camrelizumab, for treating relapsed or refractory NK/T-cell lymphoma[4].
  • Studying the effectiveness of pegaspargase in combination with other drugs like selinexor and dexamethasone for early-stage NK/T-cell lymphoma[5].

Potential Side Effects

Like all medications, pegaspargase can cause side effects. Some of the potential side effects include:

  • Allergic reactions: These can range from mild to severe and may include rash, difficulty breathing, or swelling[1].
  • Pancreatitis: Inflammation of the pancreas, which can cause abdominal pain[1].
  • Blood clotting or bleeding problems[1].
  • Liver problems: This may be indicated by increased levels of bilirubin in the blood[6].
  • Changes in blood sugar levels
  • Nausea and vomiting

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms promptly.

Combination Therapies

Pegaspargase is often used in combination with other cancer treatments to enhance its effectiveness. Some common combination therapies include:

  • P-Gemox: Pegaspargase combined with gemcitabine and oxaliplatin for treating NK/T-cell lymphoma[3].
  • ODD: Oncaspar (pegaspargase) combined with Doxil (doxorubicin) and Decadron (dexamethasone) for treating various lymphoid malignancies[2].
  • DAPT: Dexamethasone, azacytidine, pegaspargase, and tislelizumab for treating NK/T cell lymphoma[7].

These combination therapies are designed to attack cancer cells through multiple mechanisms, potentially improving treatment outcomes. However, they may also increase the risk of side effects, so close monitoring by healthcare professionals is essential.

Aspect Details
Main Indications Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin’s Lymphoma, Extranodal NK/T-cell Lymphoma
Administration Intravenous infusion or intramuscular injection
Dosage Range 2000-3750 IU/m2, varies by protocol
Combination Therapies Often combined with other chemotherapy drugs, immunotherapies, or targeted agents
Key Outcomes Measured Complete response rate, progression-free survival, overall survival, pharmacokinetics, pharmacodynamics
Safety Monitoring Allergic reactions, liver function, blood clotting, pancreatic inflammation
Ongoing Research Focus Optimal dosing, efficacy in various cancer types, combination strategies, comparison to other asparaginase formulations

FAQ

  • What is pegaspargase? Pegaspargase is a chemotherapy drug that depletes asparagine, an amino acid essential for cancer cell survival. It is a pegylated form of L-asparaginase with a longer half-life and lower risk of allergic reactions compared to the non-pegylated version.
  • What types of cancer is pegaspargase used to treat? Pegaspargase is primarily used to treat acute lymphoblastic leukemia (ALL), but is also being studied for other lymphoid malignancies like non-Hodgkin's lymphoma, Hodgkin's lymphoma, and extranodal NK/T-cell lymphoma.
  • How is pegaspargase administered? Pegaspargase is typically administered as an intravenous infusion or intramuscular injection. The dosage and frequency can vary depending on the specific treatment protocol and cancer type.
  • What are some common side effects of pegaspargase? Common side effects may include allergic reactions, liver problems, blood clotting issues, and pancreatic inflammation. Patients are usually monitored closely for these potential adverse events during treatment.
  • Why is pegaspargase being studied in clinical trials? Clinical trials are evaluating pegaspargase to determine optimal dosing, assess its efficacy in combination with other drugs, explore its use in different cancer types, and compare it to other asparaginase formulations to improve patient outcomes and reduce side effects.

Ongoing Clinical Trials on Pegaspargase

  • Study of Blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark Estonia +11

  • Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Germany

  • Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +5

  • Study of Ruxolitinib and Chemotherapy Drug Combination for Children with Acute Lymphoblastic Leukemia and JAK/STAT Pathway Activation

    Recruiting

    4 1 1 1
    Investigated drugs:
    Poland

  • Study on Lymphoblastic Lymphoma Treatment in Children and Adolescents Using Dexamethasone, Prednisone, and PEG-Asparaginase

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland Germany +8

  • Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +5

  • Study on Pegaspargase and Rituximab for Treating Children with Acute Lymphoblastic Leukemia

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Greece Hungary Slovenia

  • Study on Pegaspargase for Treating Acute Lymphoblastic Leukemia in Children and Adolescents

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

Glossary

  • Pegaspargase: A chemotherapy drug that depletes asparagine, an amino acid essential for cancer cell survival. It is a pegylated form of L-asparaginase with a longer half-life and lower risk of allergic reactions.
  • Acute Lymphoblastic Leukemia (ALL): A type of blood cancer that affects the lymphoid cells in the bone marrow, causing rapid growth of immature white blood cells called lymphoblasts.
  • Extranodal NK/T-cell Lymphoma (ENKTL): A rare and aggressive type of non-Hodgkin lymphoma that typically affects areas outside the lymph nodes, such as the nasal cavity.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and relationship between drug concentration and effect.
  • Minimal Residual Disease (MRD): The small number of cancer cells that may remain in the body during or after treatment, often undetectable by standard tests.
  • Complete Response (CR): The disappearance of all signs of cancer in response to treatment, as determined by medical tests and examinations.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a dose reduction in clinical trials.

References

  1. https://clinicaltrials.gov/study/NCT01574274
  2. https://clinicaltrials.gov/study/NCT00837200
  3. https://clinicaltrials.gov/study/NCT02533323
  4. https://clinicaltrials.gov/study/NCT06376721
  5. https://clinicaltrials.gov/study/NCT06559553
  6. https://clinicaltrials.gov/study/NCT01251809
  7. https://clinicaltrials.gov/study/NCT04899414